SEC Form 4 · accession 0000907654-26-000077
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul T Quinlan
Officer — General Counsel
Period of report
Aug 14, 2026
Accepted (ET)
Aug 14, 2026 · 5:52 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | M | 10,000 | $7.80 | A | 41,034 | D | |
| Common Stock | Aug 14, 2026 | M | 42,000 | $12.50 | A | 83,034 | D | |
| Common StockF2 | Aug 14, 2026 | S | 3,630 | $106.0504 | D | 79,404 | D | |
| Common StockF3 | Aug 14, 2026 | S | 10,434 | $107.1402 | D | 68,970 | D | |
| Common StockF4 | Aug 14, 2026 | S | 14,696 | $107.9735 | D | 54,274 | D | |
| Common StockF5 | Aug 14, 2026 | S | 10,200 | $109.1131 | D | 44,074 | D | |
| Common StockF6 | Aug 14, 2026 | S | 9,193 | $110.0039 | D | 34,881 | D | |
| Common StockF7 | Aug 14, 2026 | S | 3,847 | $111.1378 | D | 31,034 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Warrant (right to buy)F8 | $7.80 | Aug 14, 2026 | M | 10,000 | D | — | Jul 14, 2034 | Common Stock | 10,000 | 89,996 | D |
| Employee Stock Option (right to buy)F9 | $12.50 | Aug 14, 2026 | M | 42,000 | D | — | Jan 21, 2035 | Common Stock | 42,000 | 120,500 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive.
- F8The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
- F9The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.